Corvus Pharmaceuticals
CRVS
61 hedge funds and large institutions have $92.2M invested in Corvus Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 8 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
0% more funds holding
Funds holding: 61 → 61 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
1.86% less ownership
Funds ownership: 87.69% → 85.83% (-1.9%)
58% less capital invested
Capital invested by funds: $219M → $92.2M (-$127M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Puissance Capital Management
New York
|
+$1.94M |
| 2 |
Renaissance Technologies
New York
|
+$1.81M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
+$1.08M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.01M |
| 5 |
TI
Telemetry Investments
New York
|
+$921K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.67M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.04M |
| 3 |
BlackRock
New York
|
-$1.77M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.19M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$710K |
CRVS Hedge Fund Activity: Q4 2018 in Review
61 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2018, worth a combined $92.2M — down 58% from $219M a quarter earlier.
Fund positioning in CRVS was balanced in Q4 2018: 8 funds opened new positions, 8 closed out, 23 added to existing stakes and 16 trimmed.
The largest buyer was Puissance Capital Management, opening a new position worth an estimated $1.94M. The largest seller was Fidelity Investments, cutting an estimated $6.67M.
- 61 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $92.2M of Corvus Pharmaceuticals stock for Q4 2018, down 58% quarter-over-quarter.
- 8 funds opened new Corvus Pharmaceuticals positions in Q4 2018 and 8 closed out, a net change of 0 holders.
- The largest Corvus Pharmaceuticals buyer in Q4 2018 was Puissance Capital Management, an estimated $1.94M added.
- The largest Corvus Pharmaceuticals seller in Q4 2018 was Fidelity Investments, an estimated $6.67M sold.
Based on aggregated 13F filings for Q4 2018.